Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL78884 | 1.00 | NPSR1 (0.46) | NPSR1CA5ACA5BCHRM2CHRM4 | |
| Sulfuric Acid SCHEMBL11137352 | 1.00 | NPSR1 (0.46) | NPSR1CA5ACA5BCHRM2CHRM4 | |
| Sulfuric Acid SCHEMBL27883463 | 1.00 | NPSR1 (0.46) | NPSR1CA5ACA5BCHRM2CHRM4 | |
| Sulfuric Acid SCHEMBL1334876 | 1.00 | NPSR1 (0.46) | NPSR1CA5ACA5BCHRM2CHRM4 | |
| Sulfuric Acid SCHEMBL11137355 | 1.00 | NPSR1 (0.46) | NPSR1CA5ACA5BCHRM2CHRM4 | |
| Sulfuric Acid SCHEMBL29289482 | 1.00 | NPSR1 (0.46) | NPSR1CA5ACA5BCHRM2CHRM4 | |
| Sulfuric Acid SCHEMBL28627679 | 0.97 | NPSR1 (0.45) | NPSR1CA5ACA5BCHRM2CHRM4 | |
| Sulfuric Acid SCHEMBL11513250 | 0.97 | NPSR1 (0.45) | NPSR1CA5ACA5BCHRM2CHRM4 | |
| Sulfuric Acid SCHEMBL28432960 | 0.97 | NPSR1 (0.45) | NPSR1CA5ACA5BCHRM2CHRM4 | |
| Sulfuric Acid SCHEMBL28536745 | 0.97 | NPSR1 (0.45) | NPSR1CA5ACA5BCHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117897140-A | Method for preparing liposome preparation | 塞拉特药物股份有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-117897139-A | Liposome formulations of BCL inhibitors | 塞拉特药物股份有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-112543630-A | Sustained release pharmaceutical composition containing antipsychotic and use thereof | 台湾微脂体股份有限公司 | 2021-03-23 | — | — | CN | claimed |
| CN-118900689-A | Oxazolidinone liposome compositions | 阿卡格拉医药公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-108601746-B | Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery | 加利福尼亚大学董事会 | 2024-09-13 | — | — | CN | disclosed |
| CN-117897140-A | Method for preparing liposome preparation | 塞拉特药物股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117897139-A | Liposome formulations of BCL inhibitors | 塞拉特药物股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-116635009-A | Compositions and methods for delivering anticancer agents with improved therapeutic index | 纳米科技制药公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-112543630-B | Sustained release pharmaceutical composition containing antipsychotic and use thereof | 台湾微脂体股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-115974938-A | Synthesis method of sucrose heptasulfate | 辅必成（上海）医药科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115605196-A | Liposome formulations for the treatment of cancer and cancer resistance | 纳米科技制药公司（US） | 2023-01-13 | — | — | CN | disclosed |
| CN-115315252-A | Antiviral composition for preventing or treating infection or respiratory disease after exposure | 盈擘医药股份有限公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-114040750-A | Inhalable bronchodilator sustained-release composition for treating pulmonary diseases | 盈擘医药股份有限公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-107811971-B | Liposomes for drug delivery | 益普生生物制药公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-109350600-B | The composition of the aqueous and non-aqueous portions of the liposomes is designed to control the release profile of the drug | 台湾微脂体股份有限公司 | 2021-10-29 | — | — | CN | disclosed |
| EP-2968146-B1 | CONTROLLED DRUG RELEASE LIPOSOME COMPOSITION | TAIWAN LIPOSOME CO LTD (TW) | 2020-02-19 | — | — | EP | disclosed |
| US-9700511-B2 | Controlled drug release liposome composition | TLC BIOPHARMACEUTICALS, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160030340-A1 | CONTROLLED DRUG RELEASE LIPOSOME COMPOSITION | TLC BIOPHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| EP-2968146-A1 | CONTROLLED DRUG RELEASE LIPOSOME COMPOSITION | Taiwan Liposome Company, Ltd. (TW) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014145187-A1 | CONTROLLED DRUG RELEASE LIPOSOME COMPOSITION | TAIWAN LIPOSOME COMPANY, LTD. (TW) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030340-A1 | CONTROLLED DRUG RELEASE LIPOSOME COMPOSITION | LIPA, CEL, LPXN | CHRM2 4181/4885CHRM1 4520/4885CHRM3 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.